A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

By A. Ross, R. Gibbons, Gregg Stone, R. Kloner, R. Alexander. Journal of the American College of Cardiology, 2005

634 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2008, result): “infusion of adenosine was also associated with a reduction in infarct size, but clinical outcomes were not significantly improved (Table 13).(109)”
Myocardial no-reflow in humans. (2009, neutral): “Adenosine IV (89) 2,118 50 or 70 g/kg/min”
Guidelines on myocardial revascularization. (2010, background): “adenosine infusion was also associated with a reduction in infarct size, but clinical outcomes were not significantly improved [209].”
Myocardial ischemia-reperfusion injury: a neglected therapeutic target. (2013, neutral): “2005 (105); 2,118 Infusion of adenosine 50 or 70 μg/kg/min No difference in death or HHF at 6 months; post hoc analysis AMISTAD II i.”